Antitumor agent-66

Cat. No.: HY-147540: Data Sheet Handling Instructions
FAQs
Technical Support

Antitumor agent-66 (Compound 4) is an analogue/derivative of (-)-cleistenolide. Antitumor agent-66 has the potential for the research of cancer diseases.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Antitumor agent-66 화학구조

CAS No. : 2456288-81-4

사이즈		재고
MOQ		Minimum order quantity
50 mg		견적 받기
100 mg		견적 받기
250 mg		견적 받기
Other size		견적 받기

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
순도&문서
References
고객리뷰

제품 설명

Antitumor agent-66 (Compound 4) is an analogue/derivative of (-)-cleistenolide. Antitumor agent-66 has the potential for the research of cancer diseases^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	15.66 μM Compound: 4	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
HL-60	IC₅₀	32.56 μM Compound: 4	Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human HL-60 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
HeLa	IC₅₀	11.02 μM Compound: 4	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
Jurkat	IC₅₀	24.36 μM Compound: 4	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
K562	IC₅₀	3.69 μM Compound: 4	Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
MCF7	IC₅₀	2.64 μM Compound: 4	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
MDA-MB-231	IC₅₀	1.85 μM Compound: 4	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
MRC5	IC₅₀	> 100 μM Compound: 4	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 6 days by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]
Raji	IC₅₀	1.85 μM Compound: 4	Antiproliferative activity against human Raji cells assessed as reduction in cell viability measured after 6 days by MTT assay Antiproliferative activity against human Raji cells assessed as reduction in cell viability measured after 6 days by MTT assay	[PMID: 32653698]

분자량

396.78

화학식

C₁₈H₁₇ClO₈

CAS No.

2456288-81-4

SMILES

CC(O[C@@H]1C=CC(O[C@@H]1[C@H](OC(C)=O)COC(C2=CC=C(C=C2)Cl)=O)=O)=O

선적

Room temperature in continental US; may vary elsewhere.

보관

Please store the product under the recommended conditions in the Certificate of Analysis.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Benedeković G, et al. Synthesis, antiproliferative activity and SAR analysis of (-)-cleistenolide and analogues. Eur J Med Chem. 2020 Sep 15;202:112597. [Content Brief]